海利生物
(603718)
| 流通市值：49.39亿 | | | 总市值：50.46亿 |
| 流通股本：6.44亿 | | | 总股本：6.58亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 194,603,133.9 | 118,892,260.05 | 71,234,419.78 | 299,991,674.85 |
| 营业收入 | 194,603,133.9 | 118,892,260.05 | 71,234,419.78 | 299,991,674.85 |
| 二、营业总成本 | 181,325,947.83 | 113,751,155.23 | 61,195,825.19 | 291,466,513.26 |
| 营业成本 | 95,639,368.06 | 51,924,379.06 | 28,297,745.35 | 123,088,486.73 |
| 税金及附加 | 2,424,731.86 | 1,543,540.52 | 773,771.5 | 3,326,906.64 |
| 销售费用 | 36,608,576.44 | 29,219,361.37 | 15,671,779.21 | 57,740,700.18 |
| 管理费用 | 26,481,179.39 | 17,521,721.83 | 9,205,640.79 | 69,108,542.03 |
| 研发费用 | 18,474,271.48 | 12,551,614.88 | 6,604,724.12 | 29,943,685.61 |
| 财务费用 | 1,697,820.6 | 990,537.57 | 642,164.22 | 8,258,192.07 |
| 其中:利息费用 | 3,359,563.76 | 1,882,422.63 | - | 10,310,606.76 |
| 其中:利息收入 | -1,681,114.16 | -898,508.33 | -260,104.95 | 2,152,345.93 |
| 加:公允价值变动收益 | 839,783.44 | 991,202.78 | - | -2,974,348.64 |
| 加:投资收益 | 57,647,724.44 | 67,655,060.24 | 2,832,581.91 | 14,279,116.66 |
| 资产处置收益 | 720,456.01 | 709,537.03 | -3,176.12 | 84,882.26 |
| 资产减值损失(新) | 1,522,044.12 | 1,522,044.12 | 837,241.74 | -1,522,044.12 |
| 信用减值损失(新) | -5,987,115.37 | -466,247.42 | -502,430.17 | 1,854,698.37 |
| 其他收益 | 8,528,436.48 | 7,991,532.25 | 1,438,246.42 | 49,676,713.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 76,548,515.19 | 83,544,233.82 | 14,641,058.37 | 69,924,179.66 |
| 加:营业外收入 | 1,334,456.53 | 994,770.18 | 1,112,770.18 | 62,079,007.2 |
| 减:营业外支出 | 53,476.84 | 3,538.75 | 3,538.75 | 785,911.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 77,829,494.88 | 84,535,465.25 | 15,750,289.8 | 131,217,275.03 |
| 减:所得税费用 | 12,760,895.56 | 10,912,891.14 | 2,157,056.36 | 20,526,343.46 |
| 六、净利润 | 65,068,599.32 | 73,622,574.11 | 13,593,233.44 | 110,690,931.57 |
| 持续经营净利润 | 65,068,599.32 | 73,622,574.11 | 13,593,233.44 | 110,690,931.57 |
| 归属于母公司股东的净利润 | 74,698,546.73 | 81,738,413.19 | 14,235,681.29 | 121,607,849.73 |
| 少数股东损益 | -9,629,947.41 | -8,115,839.08 | -642,447.85 | -10,916,918.16 |
| (一)基本每股收益 | 0.12 | - | 0.02 | 0.19 |
| (二)稀释每股收益 | 0.12 | - | 0.02 | 0.19 |
| 八、其他综合收益 | 7,804,209.3 | 14,094,135.63 | 3,040,760 | 4,833,402.1 |
| 归属于母公司股东的其他综合收益 | 7,804,209.3 | 14,094,135.63 | 3,040,760 | 4,833,402.1 |
| 九、综合收益总额 | 72,872,808.62 | 87,716,709.74 | 16,633,993.44 | 115,524,333.67 |
| 归属于母公司股东的综合收益总额 | 82,502,756.03 | 95,832,548.82 | 17,276,441.29 | 126,441,251.83 |
| 归属于少数股东的综合收益总额 | -9,629,947.41 | -8,115,839.08 | -642,447.85 | -10,916,918.16 |
| 公告日期 | 2023-10-31 | 2023-08-29 | 2023-04-28 | 2023-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |